undamentalytics Newsletter
Sign in

Hutchmed (china) Ltd (HCM) stock

Add to watchlist

Add holding +

NASDAQ: HCM Nasdaq Biotechnology

B Fundamentals grade

Hutchmed (china) Ltd is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: after-tax interest is 65% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

Price vs value

Under review: after-tax interest is 65% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy. We'll show the comparison once resolved.

Hutchmed (china) Ltd valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds23 adding, 27 cuttingOf 6 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Hutchmed (china) files

Where Hutchmed (china) stands after its latest Filing

Revenue for the twelve months was $549m, down 13.0% on a year earlier, a smaller fall than the 24.8% decline a quarter earlier. Free-cash-flow margin rose to -14.4% from -62.0% a year earlier. Operating margin widened to -7.1% from -92.2%. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 3 of our 7 financial-health checks.

Our model value for Hutchmed (china) is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Hutchmed (china) Ltd's trailing-twelve-month revenue fell 13.0% year on year, with a free-cash-flow margin of -14.4%. Where it stands out: net margin of 83.3% ranks 2 of 180 biotechnology companies we cover. Where it lags: gross margin of 38.7% ranks 69 of 75 biotechnology companies we cover.

Our discounted-cash-flow model values the business at ~$7.7 per share in the base case (~$7.5–$7.9 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 352.0% while net income grew 1111.0%: a 1463pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Hutchmed (china) Ltd's latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 13.0% over the last 12 months.
  • Loss-making. Operating margin is -7.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -14.4% of revenue over the last 12 months.
  • Gross margin slipping. Gross margin is down 6.0 points on a year ago.
  • Weak cash conversion. Free cash flow was -17% of net income over the last 12 months.

Price chart

  • 1 day-1.2%
  • 1 week-5.0%
  • 1 month-7.7%
  • This year-0.5%
  • 1 year-14.4%
  • 5 years-57.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$549M
Operating margin
-7.1%
Net margin
83.3%
EPS (TTM, diluted)
$2.62

Growth

Revenue growth
−13.0%
Change in growth rate
+11.8 pts
Share count change
+0.0%

Cash

Free cash flow (TTM)
-$78.8M
FCF margin
-14.4%
Stock pay % of revenue
2.6%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for HCM from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Hutchmed (china) Ltd valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: after-tax interest is 65% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Hutchmed (china) Ltd as an operating company, with every model that fits that kind of business. Cost of equity 9.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.93 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$25 ~$21–$55 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$0.8 ~$0.4–$1.5 Left out: out of range vs price (0.06x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Hutchmed (china) Ltd with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025
Share price$13.57$39.42$23.09$25.07$32.02$35.08$14.78$18.11$14.41$13.33
Market value$1.6bn$4.9bn$3.1bn$3.3bn$4.5bn$5.6bn$2.5bn$3.1bn$2.5bn$2.3bn
+ Net debt (− = net cash)−$13m−$55m−$59m−$94m−$209m−$351m−$295m−$173m−$48m$47m
Enterprise value$1.6bn$4.8bn$3.0bn$3.2bn$4.3bn$5.2bn$2.2bn$3.0bn$2.5bn$2.4bn
Multiples
Price / sales 7.5x20.2x14.3x16.3x19.6x15.6x5.9x3.8x4.0x4.2x
Price / earnings 139.1x——————31.2x66.7x5.1x
Price / free cash flow ———————16.9x——
EV / EBITDA ———————111.9x——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current — — $627m +14%
Next — — $699m +12%

Analyst recommendations

12 analysts, Oct 2026
Buy1083%
Hold217%
Sell00%

Monthly trend

  1. Oct 202619212
  2. Sep 202629213
  3. Aug 202627413
  4. Jul 202628313

Counts of recommendations published by analysts covering Hutchmed (china) Ltd, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.3%
of tradable shares
Days to cover
4.66
at average volume
Short interest, 1 month
+15%
to October 15, 2026
Held by institutions
3%
of shares
Held by insiders
0.0%
of shares
Employees
1,790
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
HCM+10%−58%+23%−20%−8%−1%
Industry peers (median)−36%−56%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
HCM50%42%50%50%33%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
HCM−36%−79%−46%−35%−31%−38%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since March 16, 2016: 82% from August 9, 2021 to October 25, 2022. Getting back needed a 461% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$9.99 – $16.05
From 52-week high
−17.3%
vs 50-day average
−2.9%
vs 200-day average
+0.4%
Volatility (1 year)
39%
Beta vs S&P 500
0.75

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Hutchmed (china) Ltd in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Hutchmed (china) Ltd
$0 $500M $1B FY14 Q4 FY17 Q4 FY20 Q4 FY25 Q4 Revenue (TTM), FY14 Q4: $87.3M Revenue (TTM), FY15 Q4: $178.2M Revenue (TTM), FY16 Q4: $216.1M Revenue (TTM), FY17 Q4: $241.2M Revenue (TTM), FY18 Q4: $214.1M Revenue (TTM), FY19 Q4: $204.9M Revenue (TTM), FY20 Q4: $228M Revenue (TTM), FY21 Q4: $356.1M Revenue (TTM), FY22 Q4: $426.4M Revenue (TTM), FY23 Q4: $838M Revenue (TTM), FY24 Q4: $630.2M Revenue (TTM), FY25 Q4: $548.5M $548.5M

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue (TTM)
FY14 Q4 $87.3M
FY15 Q4 $178.2M
FY16 Q4 $216.1M
FY17 Q4 $241.2M
FY18 Q4 $214.1M
FY19 Q4 $204.9M
FY20 Q4 $228M
FY21 Q4 $356.1M
FY22 Q4 $426.4M
FY23 Q4 $838M
FY24 Q4 $630.2M
FY25 Q4 $548.5M
Revenue growth, TTM YoY Hutchmed (china) Ltd
-50% 0% 50% 100% 150% FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue growth, TTM YoY, FY15 Q4: 104.1% Revenue growth, TTM YoY, FY16 Q4: 21.3% Revenue growth, TTM YoY, FY17 Q4: 11.6% Revenue growth, TTM YoY, FY18 Q4: -11.2% Revenue growth, TTM YoY, FY19 Q4: -4.3% Revenue growth, TTM YoY, FY20 Q4: 11.3% Revenue growth, TTM YoY, FY21 Q4: 56.2% Revenue growth, TTM YoY, FY22 Q4: 19.7% Revenue growth, TTM YoY, FY23 Q4: 96.5% Revenue growth, TTM YoY, FY24 Q4: -24.8% Revenue growth, TTM YoY, FY25 Q4: -13.0% -13.0%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue growth, TTM YoY
FY15 Q4 104.1%
FY16 Q4 21.3%
FY17 Q4 11.6%
FY18 Q4 -11.2%
FY19 Q4 -4.3%
FY20 Q4 11.3%
FY21 Q4 56.2%
FY22 Q4 19.7%
FY23 Q4 96.5%
FY24 Q4 -24.8%
FY25 Q4 -13.0%
Operating margin (TTM) Hutchmed (china) Ltd
-100% -50% 0% 50% FY14 Q4 FY17 Q4 FY20 Q4 FY25 Q4 Operating margin (TTM), FY14 Q4: -20.9% Operating margin (TTM), FY15 Q4: -5.5% Operating margin (TTM), FY16 Q4: -21.6% Operating margin (TTM), FY17 Q4: -22.1% Operating margin (TTM), FY18 Q4: -43.3% Operating margin (TTM), FY19 Q4: -71.4% Operating margin (TTM), FY20 Q4: -86.3% Operating margin (TTM), FY21 Q4: -92.2% Operating margin (TTM), FY22 Q4: -95.6% Operating margin (TTM), FY23 Q4: 2.2% Operating margin (TTM), FY24 Q4: -6.9% Operating margin (TTM), FY25 Q4: -7.1% -7.1%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Operating margin (TTM)
FY14 Q4 -20.9%
FY15 Q4 -5.5%
FY16 Q4 -21.6%
FY17 Q4 -22.1%
FY18 Q4 -43.3%
FY19 Q4 -71.4%
FY20 Q4 -86.3%
FY21 Q4 -92.2%
FY22 Q4 -95.6%
FY23 Q4 2.2%
FY24 Q4 -6.9%
FY25 Q4 -7.1%
FCF margin (TTM) Hutchmed (china) Ltd
-100% -50% 0% 50% FY14 Q4 FY17 Q4 FY20 Q4 FY25 Q4 FCF margin (TTM), FY14 Q4: 5.3% FCF margin (TTM), FY15 Q4: -7.1% FCF margin (TTM), FY16 Q4: -6.4% FCF margin (TTM), FY17 Q4: -5.8% FCF margin (TTM), FY18 Q4: -18.3% FCF margin (TTM), FY19 Q4: -43.7% FCF margin (TTM), FY20 Q4: -30.7% FCF margin (TTM), FY21 Q4: -62.0% FCF margin (TTM), FY22 Q4: -71.6% FCF margin (TTM), FY23 Q4: 22.3% FCF margin (TTM), FY24 Q4: -2.8% FCF margin (TTM), FY25 Q4: -14.4% -14.4%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period FCF margin (TTM)
FY14 Q4 5.3%
FY15 Q4 -7.1%
FY16 Q4 -6.4%
FY17 Q4 -5.8%
FY18 Q4 -18.3%
FY19 Q4 -43.7%
FY20 Q4 -30.7%
FY21 Q4 -62.0%
FY22 Q4 -71.6%
FY23 Q4 22.3%
FY24 Q4 -2.8%
FY25 Q4 -14.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F, 20-F/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 87 178 216 241 214 205 228 356 426 838 630 549
Gross profit — — — — — — — — 115 454 281 212
EBITDA −17 −8 −44 −51 −89 −141 −191 −321 −399 27 −31 −26
Operating income −18 −10 −47 −53 −93 −146 −197 −328 −408 18 −44 −39
Net income −7 8 12 −27 −75 −106 −126 −195 −361 101 38 457
Diluted EPS — — $0.10 −$0.21 −$0.56 −$0.80 −$0.90 −$1.25 −$2.15 $0.60 $0.20 $2.60
Growth (year on year)
Revenue — +104.1% +21.3% +11.6% −11.2% −4.3% +11.3% +56.2% +19.7% +96.5% −24.8% −13.0%
EBITDA — — — — — — — — — — −218.0% —
Operating income — — — — — — — — — — −337.9% —
Net income — — +46.4% −328.6% — — — — — — −62.6% +>999%
Diluted EPS — — — −315.0% — — — — — — −66.7% +>999%
Margins
Gross margin — — — — — — — — 27.0% 54.1% 44.6% 38.7%
EBITDA margin −19.5% −4.4% −20.5% −21.1% −41.6% −69.0% −83.6% −90.2% −93.6% 3.2% −5.0% −4.7%
Operating margin −20.9% −5.5% −21.6% −22.1% −43.3% −71.4% −86.3% −92.2% −95.6% 2.2% −6.9% −7.1%
Net margin −8.4% 4.5% 5.4% −11.1% −34.9% −51.7% −55.2% −54.7% −84.6% 12.0% 6.0% 83.3%
Free-cash-flow margin 5.3% −7.1% −6.4% −5.8% −18.3% −43.7% −30.7% −62.0% −71.6% 22.3% −2.8% −14.4%
Cash flow
Cash from operations 8 −9 −10 −9 −33 −81 −62 −204 −269 219 0 −65
Capital spending 4 3 4 5 6 9 8 16 37 33 18 14
Free cash flow 5 −13 −14 −14 −39 −89 −70 −221 −305 187 −17 −79
Stock-based pay — 0 3 3 11 9 16 36 40 30 30 14
Free cash flow after stock pay — −13 −17 −17 −50 −99 −86 −257 −345 157 −48 −93
Balance sheet
Cash 39 32 79 85 86 121 236 378 313 284 154 71
Total debt 0 73 67 30 27 27 27 27 18 110 106 118
Net debt (negative = net cash) −39 41 −13 −55 −59 −94 −209 −351 −295 −173 −48 47
Diluted shares 105m 109m 120m 123m 133m 133m 140m 159m 169m 174m 175m 175m
Returned to shareholders
Buybacks — 2 1 1 5 0 13 27 48 9 36 —
Total returned — 2 1 1 5 0 13 27 48 9 36 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 7 checks passed · December 31, 2025
What it owns · $1.8bn
Short-term assets $1.6bnLonger-term assets $186m
What it owes, and who funded it · $1.7bn
Short-term liabilities $316mLonger-term liabilities $186mShareholders' equity $1.2bn
  • Short-term assets cover short-term liabilities $1.6bn of assets due within a year against $316m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.6bn short-term assets against $186m of longer-dated liabilities.
  • More cash than debt $71m of cash against $93m of debt.
  • Debt below 40% of shareholders' equity Debt is 8% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 6% to 8% over five years.
  • A year's operating cash flow covers at least 20% of debt −$65m of operating cash flow against $93m of debt.
  • Operating profit covers interest at least five times over Operating income of −$39m against $3m of interest.

From Hutchmed (china) Ltd's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2024 Q4 TTM
Buybacks (TTM)
$36.1M
Returned to shareholders
-207%
of free cash flow
Buybacks, last 3 fiscal years
$93.2M
Diluted share count
+0.0%
year over year
Total shareholder yield
1.6%
dividends 0.0% + buybacks 1.6% of market value
R&D spending
27.0%
of revenue
Days sales outstanding
84 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated HCM ADMA TARS MIRM KRYS ARQT Median
Revenue, last 12 months $549m $512m $606m $618m $470m $464m $56m
Revenue growth, last 12 months −13.0% 8.0% 105.2% 44.0% 26.0% 76.1% 12.6%
Revenue growth, 3-year average — 35.0% 264.7% 74.8% 280.1% 241.4% 13.7%
Revenue growth, latest quarter — 2.0% 69.4% 37.9% 30.2% 59.3% 10.2%
Gross margin 38.7% 64.7% — — — 91.1% 82.9%
Operating margin −7.1% 43.8% −8.0% −134.9% 48.4% 7.4% −189.4%
Operating margin, 3-year average −40.5% 34.0% −76.2% −63.1% 34.1% −53.8% −363.5%
Net margin 83.3% 33.0% −7.7% −139.2% 47.9% 6.1% −169.8%
Cash from operations / revenue −11.8% 26.7% 12.2% −36.8% 68.9% 8.5% −168.0%
Free-cash-flow margin −14.4% 22.7% 9.2% −37.0% 66.0% 8.4% −162.4%
Free-cash-flow margin, 3-year average −27.4% 18.9% −56.4% −14.7% 44.8% −50.3% −310.0%
Stock pay / revenue 2.6% 4.5% 8.5% 16.8% 11.8% 9.4% 20.0%
Change in share count 0.0% −3.2% 8.0% 15.3% 2.3% 17.3% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -13.0% 12.6% 121 of 172
Change in growth rate Growth +11.8pp -0.1pp 43 of 172
Gross margin Profitability 38.7% 82.4% 69 of 75
Operating margin Profitability -7.1% -189.4% 42 of 175
Net margin Profitability 83.3% -157.3% 2 of 180
Free-cash-flow margin Cash generation -14.4% -145.4% 53 of 176
Stock pay as % of revenue Cash generation 2.6% 19.2% 16 of 179
Long-term debt as % of assets Balance sheet 3.9% 20.6% 18 of 78
Change in share count Balance sheet 0.0% 7.9% 21 of 156
Days sales outstanding Balance sheet 84 days 75 days 56 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$51.8M
Institutions reporting
56
Shares held vs prior quarter
▲ 5.0%
Positions opened / closed
9 / 5

Top buyers and sellers, Q2 2026: 23 institutions bought and 27 sold ; the biggest buyer was Jane Street Group, LLC (+118K shares) and the biggest seller Tidal Investments LLC (−67K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Schroder Investment Management Group $15.8M 1.5M 30.5% 0.0%
Allianz Asset Management Gmbh $12.5M 837K 24.2% 0.0%
State Street Corp $3.4M 314K 6.5% ▲ 2.9%
Aia Group Ltd $3.1M 291K 6.0% 0.0%
M&G PLC $2.7M 243K 5.2% ▼ 5.0%
Amundi $2.2M 204K 4.2% ▼ 12.0%
Jane Street Group, LLC $2.1M 194K 4.0% ▲ 154.2%
Renaissance Technologies LLC $1.4M 130K 2.7% ▼ 1.4%
BNP Paribas Financial Markets $1.1M 104K 2.2% ▼ 2.0%
Xy Capital Ltd $1.1M 104K 2.2% ▲ 115.2%
Crossmark Global Holdings, Inc. $913,685 85K 1.8% ▼ 0.1%
Acadian Asset Management LLC $696,000 65K 1.3% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Hutchmed (china) Ltd's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K

Data status

When each part of this page on Hutchmed (china) Ltd was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Hutchmed (china) Ltd in brief

What does Hutchmed (china) Ltd do?
Hutchmed (china) Ltd is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Hutchmed (china) Ltd's stock ticker?
Hutchmed (china) Ltd trades under the ticker HCM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Hutchmed (china) Ltd's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Hutchmed (china) Ltd reported revenue of $549M, 13.0% lower than a year earlier, according to its SEC filings.
What is Hutchmed (china) Ltd's free cash flow?
Hutchmed (china) Ltd's free-cash-flow margin is -14.4% of revenue over the trailing twelve months, ranking 53 of the 176 biotechnology companies we cover.
Who are Hutchmed (china) Ltd's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Schroder Investment Management Group, Allianz Asset Management Gmbh and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Hutchmed (china) Ltd buying back stock, and does it pay a dividend?
Hutchmed (china) Ltd spent $36.1M on share repurchases over the trailing twelve months, and its diluted share count still rose 0.0% over the year.
What is Hutchmed (china) Ltd's market cap?
On December 31, 2025, Hutchmed (china) Ltd's market capitalisation was about $2.3B, with a price-to-earnings ratio of 5.1 and net debt of $46.8M. Market figures come from third-party market data and may be delayed.
How much debt does Hutchmed (china) Ltd have?
Hutchmed (china) Ltd's debt-to-equity ratio is 7.5%, from its latest balance sheet (5.5% five years earlier). The financial health section below sets out its other solvency checks.
Who are Hutchmed (china) Ltd's competitors?
In our Biotechnology peer group, the companies closest to Hutchmed (china) Ltd are Adma Biologics, Inc., Tarsus Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc., Krystal Biotech, Inc. and Arcutis Biotherapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Hutchmed (china) Ltd's.